Supreme Court Refuses to Draw Line for Adverse Event Reports
By Mari Serebrov
Thursday, March 24, 2011
A U.S. Supreme Court ruling will have biopharmaceutical companies walking a fine line when it comes to disclosing adverse event reports to their investors, but the court refused to define that line.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.